SCHEMBL4772328

SCHEMBL4772328

NC(Cc1ccc(Cl)cc1Cl)CN1CCOCC1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2A13 Q16696 2/20 0.62
HDAC8 Q9BY41 6/20 0.44
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
TSHR P16473 1/20 0.43
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
ATM Q13315 1/20 0.43
SIGMAR1 Q99720 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
P2RX7 Q99572 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5756812 0.84 HPGD (0.46) CYP2A13HDAC8HDAC3HDAC1HDAC2
SCHEMBL4910361 0.77 HDAC8 (0.66) CYP2A13HDAC8HDAC3HDAC1HDAC2
SCHEMBL4109682 0.77 CYP2A13 (1.00) CYP2A13TSHRMAPTTP53MAPK1
SCHEMBL6008837 0.75 SLC6A2 (0.56) MAPTHTTATMSIGMAR1
Hydrochloric Acid SCHEMBL6007340 0.74 SLC6A2 (0.55) MAPTHTTATMSIGMAR1
SCHEMBL22116199 0.72 IDO1 (0.48) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL30308976 0.72 IDO1 (0.48) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL13948297 0.71 CYP2A13 (0.54) CYP2A13HDAC8HDAC3HDAC1HDAC2
SCHEMBL2520231 0.71 IDO1 (0.47) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL2520228 0.71 IDO1 (0.47) HDAC8HDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed